ORYZON to present trial in progress Phase Ib FRIDA study at the upcoming 2023 ASCO annual meeting

by Oryzon Genomics

Oryzon today announced the presentation of the trial in progress (TIP) FRIDA poster entitled Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myelo...

Read more

ORYZON reports financial results and corporate update for quarter ended March 31, 2023

by Oryzon Genomics

Oryzon Genomics, S.A. a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first ...

Read more

ORYZON to give updates on corporate progress in May-June

by Oryzon Genomics

Oryzon Genomics announced today that its management will give an update on corporate progress at several international events on May-June

Read more

ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b adaptive trial in Borderline Personality Disorder

by Oryzon Genomics

Oryzon Genomics S.A., announced today positive outcome from its planned, prespecified interim analysis of its Phase 2b trial, PORTICO, with vafidemstat for borderline personality disorder (BPD). These...

Read more

ORYZON announces First Patient In in FRIDA, a Phase Ib trial with iadademstat in relapsed/refractory FLT3-mutant acute myeloid leukemia patients

by Oryzon Genomics

Oryzon Genomics announced today the enrollment of the first patient in its Phase Ib trial of iadademstat in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia (A...

Read more

ORYZON announces clinical candidate nomination of ORY-4001 for the treatment of CNS disorders

by Oryzon Genomics

Oryzon Genomics, S.A, announced today the nomination of ORY-4001, a selective histone deacetylase 6 (HDAC-6) inhibitor, as clinical development candidate for the treatment of certain neurological dise...

Read more

ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology

by Oryzon Genomics

Oryzon Genomics S.A. announced that it will host a virtual panel discussion discussing the unmet medical needs in specific central nervous system (CNS) and oncology diseases, such as Borderline Person...

Read more

ORYZON reports financial results and corporate update for quarter ended December 31, 2022

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...

Read more

ORYZON to give updates on corporate progress in February-March

by Oryzon Genomics

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...

Read more

ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas

by Oryzon Genomics

It has been announced today the enrollment of the first patient in a Phase II collaborative study with iadademstat in patients with relapsed/refractory high grade neuroendocrine carcinomas (NEC).

Read more

ORYZON se une a la Alianza para la Vacunación Infantil

by Oryzon Genomics

La aportación de Oryzon se destinará a distribuir la vacuna neumocócica en Mozambique y Etiopía para prevenir la neumonía, la mayor causa de mortalidad infantil por enfermedad infecciosa a escala...

Read more

ORYZON primera empresa en España en inversión en I+D por empleado

by Oryzon Genomics

Oryzon Genomics, S.A., de acuerdo al ranquin publicado por la Unión Europea, es la empresa española con mayor intensidad de inversión en I+D por empleado y que ocupa el numero 20 en el listado de 2...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Identifican nuevos mecanismos implicados...

by CIMA - Centro de Investigación Médica Aplicada

Investigadores del Cima y de la Clínica Universidad de Navarra confir...

Photos Stream